Video

Dr. Cherington on the Use of Immunotherapy and Targeted Therapy in Lung Cancer

Chad Cherington, MD, discusses the use of immunotherapy and targeted therapy in lung cancer.

Chad Cherington, MD, medical oncologist and hematologist, Ironwood Cancer and Research Centers, discusses the use of immunotherapy and targeted therapy in lung cancer.

The role of targeted therapy has grown significantly over the past few years as more targets have been identified and agents have become available for clinical use, says Cherington. Moreover, some patients are able to be treated with sequential targeted therapies.

However, frail and elderly patients with PD-L1—positivity <50% are typically given chemotherapy as opposed to targeted therapy because of their performance status, explains Cherington.

Developing novel agents to utilize earlier in the treatment of these patients may enhance outcomes, says Cherington.

Additionally, further investigation into optimizing treatment for patients who progress on immunotherapy is needed. Currently, data regarding the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in advanced non—small cell lung cancer suggest that dual immunotherapy could become another frontline option for patients, concludes Cherington.

Related Videos
Timothy Gershon, MD, PhD
Jordan Hansford, MD
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD